[{"id":"c5b73a52-46ba-4836-95bd-c175161b13a0","acronym":"SPICE","url":"https://clinicaltrials.gov/study/NCT02636036","created_at":"2021-04-09T00:54:47.675Z","updated_at":"2025-02-25T14:36:03.548Z","phase":"Phase 1","brief_title":"Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors","source_id_and_acronym":"NCT02636036 - SPICE","lead_sponsor":"PsiOxus Therapeutics Ltd","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • enadenotucirev (ColoAd1)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 01/25/2016","start_date":" 01/25/2016","primary_txt":" Primary completion: 10/08/2021","primary_completion_date":" 10/08/2021","study_txt":" Completion: 10/08/2021","study_completion_date":" 10/08/2021","last_update_posted":"2021-11-09"},{"id":"8eb34a84-c6fa-4675-b719-ac9d9f2f4167","acronym":"OCTAVE","url":"https://clinicaltrials.gov/study/NCT02028117","created_at":"2021-01-18T09:17:15.438Z","updated_at":"2024-07-02T16:36:30.312Z","phase":"Phase 1","brief_title":"Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients","source_id_and_acronym":"NCT02028117 - OCTAVE","lead_sponsor":"PsiOxus Therapeutics Ltd","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enadenotucirev (ColoAd1)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 11/19/2019","primary_completion_date":" 11/19/2019","study_txt":" Completion: 11/19/2019","study_completion_date":" 11/19/2019","last_update_posted":"2021-05-13"}]